Endocannabinoid levels differed in RA and tracked disease activity in women

Significant changes in circulating endocannabinoids correlate with disease severity in rheumatoid arthritis: a cross-sectional study.

Rheumatology (Oxford, England) • • Highly Relevant
šŸ¤–

AI Summary

This single-center, cross-sectional study asked whether circulating endocannabinoids and related molecules differ in rheumatoid arthritis (RA) and track disease activity. Researchers measured plasma levels of 25 molecules in 43 women with RA and 38 healthy female controls; the analysis adjusted for age and cannabis use. Several molecules, including palmitoylethanolamide (PEA), were higher in the RA group, while anandamide (AEA) and two other measured molecules were lower.

šŸ’” Key Findings

1
Compared with healthy controls, women with RA had higher levels of several measured endocannabinoids and related molecules, including PEA, and lower levels of AEA and two other molecules.
Good
65%
2
Plasma levels of AEA, PEA, and oleoylethanolamide (OEA) were significantly associated with DAS28-ESR disease-activity scores; the abstract does not specify the direction of each association.
Good
65%
3
The findings suggest these molecules may warrant investigation as biomarkers or therapeutic targets, but this cross-sectional study cannot establish cause and effect or show that changing their levels would treat RA.
High
85%

šŸ“„ Original Abstract

OBJECTIVE: To investigate alterations in plasma concentrations of circulating endocannabinoids and endocannabinoid-like molecules in patients with rheumatoid arthritis (RA) and to assess their associations with the Disease Activity Score 28 with Erythrocyte Sedimentation Rate (DAS28-ESR). METHODS: The study was designed as a single-center, cross-sectional investigation. Female patients with RA (n = 43; aged ≄18 years) were recruited at Sheba Medical Center, Israel, and diagnosed according to the 2010 ACR/EULAR classification criteria. Healthy females (n = 38) served as controls. Plasma levels of 25 endocannabinoids and endocannabinoid-like molecules were quantified using solid-phase extraction followed by electrospray ionization liquid chromatography-high-resolution tandem mass spectrometry (ESI-LC-HRMS/MS). Statistical analyses included group comparisons and FDR-corrected linear regression models assessing associations between DAS-28-ESR and metabolite levels, adjusted for age and cannabis use. RESULTS: Several endocannabinoids, including 2-arachidonyl glycerol ether (2-AGE), 2-linoleoyl glycerol (2-LG), 2-oleoyl glycerol (2-OG), 2-palmitoyl glycerol (2-PG), 2-SG, linoleoyl-phenylalanine, linolenic acid (LnA), N-O-leucine, and palmitoylethanolamide (PEA), were significantly elevated in RA patients compared with controls (p = 0.015, p < 0.001, p < 0.001, p < 0.001, p = 0.027, p < 0.001, p = 0.034, p < 0.001, and p = 0.002, respectively). In contrast, anandamide (AEA), N-oleoyl alanine, and O-AEA were significantly reduced (p = 0.012, p < 0.001, and p < 0.001, respectively). Notably, plasma levels of AEA, PEA, and oleoylethanolamide (OEA) correlated significantly with DAS28-ESR scores (p = 0.015, p = 0.008, and p = 0.012, respectively). CONCLUSION: Specific endocannabinoids and endocannabinoid-like molecules are dysregulated in RA and correlate with disease activity, suggesting potential roles as biomarkers and therapeutic targets.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.